Acrivon expands Akoya companion diagnostic deal to $17.3M for ACR-368 OncoSignature test

Acrivon Therapeutics, Inc.

Third Amendment with Akoya increases total milestone payments to $17.3M through FDA pre-market approval for multiple indications.
$3.8M in milestones already achieved and paid to date; cash runway unchanged from Nov 2023 10-Q.
Expanded scope of work covers development of ACR-368 companion diagnostic test across multiple indications.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Acrivon Therapeutics, Inc. amended OncoSignature Diagnostic Agreement with Akoya Biosciences, Inc. valued at $17,300,000 (effective 2023-12-04).

Action: amendment
Agreement: collaboration
Counterparty: Akoya Biosciences, Inc.
Value: $17,300,000
Effective: 2023-12-04

Exact text from the filing

On December 4, 2023, Acrivon Therapeutics, Inc. (the “Company”) entered into a Third Amendment to the OncoSignature Diagnostic Agreement (the “Third Amendment”) with Akoya Biosciences, Inc. (“Akoya”) for the development of the ACR-368 OncoSignature companion diagnostic test.

View on SEC.gov

Browse all material agreements →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-291705

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.